Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Xceed Molecular signs up Center for Molecular Medicine to new Strategic Collaborator programme

Xceed Molecular : 29 November, 2007  (New Product)
Xceed Molecular has launched its Strategic Collaborator programme and signed its first member, the Center for Molecular Medicine (CMM), of Grand Rapids, Michigan, USA.
According to Xceed's president and CEO, David Deems, the Strategic Collaborator programme is a mutually beneficial agreement with a high-profile institution or investigator designed to propel the partners' clinical research, while providing Xceed with additional real-world clinical-laboratory experience and access to critical research results.

The programme is an integral part of the company's strategy to add assays to its pipeline of condition- or pathway-specific Signature Chips that will be available both as catalogue products and through Xceed's Expression Services.

Through the programme, Xceed will provide the Ziplex System or Expression Services to the collaborator at no or low cost in return for a commitment for future publication, access to Biomarker content, or assistance with product development or services.

'The Center for Molecular Medicine, under the leadership of Daniel H Farkas, PhD, HCLD, is an ideal partner for Xceed,' said Deems. 'Dr Farkas and his team will undertake a number of projects as part of our agreement, including the investigation and development of cancer diagnostics and improved sample-preparation methods.' Internationally renowned for his work in molecular diagnostics, Dr Farkas joined the CMM as executive director in December 2006. His peers voted him the recipient of the Association for Molecular Pathology Leadership Award winner for 2007.

Commenting on the collaboration, Dr Farkas said, 'We are very pleased to be supporting Xceed's efforts to bring its clinical laboratory-friendly Ziplex System to the marketplace. The intersection of patient care and business represented by our international collaboration is central to the mission of the Center for Molecular Medicine. As a CLIA-certified, CAP-accredited laboratory, the CMM will provide Xceed the opportunity to bring new array-based tests to the clinical community. The ease of use and initial data generated by the Ziplex System has been impressive. As translational medicine moves from the research laboratory to the clinic, technology that is affordable, reliable, and automated will be critical. We believe the Ziplex System is uniquely positioned to fulfil this need. The resulting benefit to patients is an excellent example of how genomic medicine will move forward in the 21st century.'

Xceed has already committed to several other institutions under its Strategic Collaborator programme and will be installing the Ziplex System at additional sites before year-end. The company's goal is to have 10 Strategic Collaborator agreements in North America by the second quarter of 2008.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo